I am extremely confused but hopefully I am wrong about your opinion. In the corporate update, each one of the bullet points explain why the drug is dead in the water. The last bullet point clearly innuendos that they are either going to rm or purchase an asset to develop.
Can you please do me a huge favor and dissect the bullet points below and explain how you pull any possible way that you see a way forward for their hgh drug??? Further more I cannot imagine Teijin releasing their interest if there was any way possible for a future. Please advise.
Corporate Update
Based on a full review of the data from the Phase 3 VELOCITY trial, feedback from the FDA during the development of somavaratan, and an objective assessment by external regulatory experts, the company believes it could not successfully file for approval based on the existing dataset.
All current clinical trials of somavaratan have been concluded and the U.S. Investigational New Drug Application (IND) and equivalent filings in other countries have been withdrawn. Additionally, in January 2018, Teijin Limited (Teijin) terminated its license agreement for somavaratan in Japan following its evaluation of the VELOCITY trial results.
The investment and delay in time-to-market that further development would require significantly impact the business case for somavaratan, given the potential that one or more long-acting growth hormone products may already be commercialized for pediatric growth hormone deficiency during that time.
The company is focused on evaluating strategic opportunities to leverage its expertise and resources to create value for shareholders. Cowen is assisting the company in reviewing possible transactions, including strategic combinations and opportunities to diversify the Versartis pipeline.
